The market opportunity for facial injectables is an attractive one–it's likely to grow more than 11.5% globally from $6.5 billion last year to $7.2 billion in 2o2o, according to a recent market research report by Grand View Research Inc. in San Francisco.
A drug’s early success into glabellar frown line studies is leading to its clinical consideration for pain management and therapy. Botulinum neurotoxin serotype E (EB-001), a potential alternative to botulinum neurotoxin serotype A (BOTOX) for frown line treatment, will be using Phase II trial data to set dosing for Phase II pain therapy indication studies in 2 models. [...]
Bonti, Newport Beach, Calif., said its EB-001, for the treatment of frown lines, achieved positive results in a Phase IIa study.
Bonti, a privately-held, clinical-stage biotechnology company, today announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar (frown) lines. The study achieved its objectives and confirmed both favorable safety and the expected clinical efficacy profile. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action [...]
Time Magazine Spotlights Neurotoxins’ Vast Medical Treatments Breadth With Botox® Cover Story. Forget wrinkles. Botox is now being used to treat migraines, depression, twitching eyes, overactive bladders, sweaty palms and more. Some call it a marvel of medicine; others caution the risks are still unknown. Inside the exploding business and strange science of Botox January 19, 2017 http://time.com/magazine/us/4623396/january-16th-2017-vol-189-no-3-u-s/